Effects of ulinastatin therapy in deep vein thrombosis prevention after brain tumor surgery: A single-center randomized controlled trial

Table 1 Comparison of baseline data, n (%)

	UTI group (n = 180)	Placebo group (n = 181)	P value
Age (yr, mean ± SD)	58.7 ± 4.2	59.1 ± 4.3	0.372
Gender			0.881
Male	109 (60.56)	111 (61.33)
Female	71 (39.44)	70 (38.67)
BMI (kg/cm2, mean ± SD)	22.1 ± 2.1	22.5 ± 2.4	0.090
Smoking history			0.561
Yes	73 (40.56)	68 (37.57)
No	107 (59.44)	113 (62.43)
Living environment			0.393
Town	126 (70.00)	134 (74.03)
Countryside	54 (30.00)	47 (25.97)
Past medical history
Hypertension	65 (36.11)	60 (33.15)	0.554
Hyperlipidemia	76 (42.22)	69 (38.12)	0.427
Diabetes	59 (32.78)	52 (28.73)	0.405
Cholelithiasis	31 (17.22)	35 (19.34)	0.603
Brain tumor type			0.355
Benign tumor	114 (63.33)	123 (67.96)
Malignant tumor	66 (36.67)	58 (32.04)
Surgery time (h, mean ± SD)	4.6 ± 1.5	4.4 ± 1.4	0.191

BMI: Body mass index; UTI: Ulinastatin.